Postnatal progression of bone disease in the cervical spines of mucopolysaccharidosis I dogs

Bone

Volumn 55, Issue 1, 2013, Pages 78-83

  Chiaro, Joseph A ^a   Baron, Matthew D ^a   del Alcazar, Chelsea M ^a   O'Donnell, Patricia ^b   Shore, Eileen M ^a   Elliott, Dawn M ^c   Ponder, Katherine P ^d   Haskins, Mark E ^b   Smith, Lachlan J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c University of Delaware   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Development; Glycosaminoglycans; Mucopolysaccharidosis; Odontoid process; Spine; Trabecular bone

Indexed keywords

AGE; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MINERALIZATION; CARTILAGE; CERVICAL SPINE; CONTROLLED STUDY; EPIPHYSIS; GROWTH PLATE; HISTOPATHOLOGY; MICRO-COMPUTED TOMOGRAPHY; MUCOPOLYSACCHARIDOSIS; NONHUMAN; ODONTOID PROCESS; PERINATAL DEVELOPMENT; TRABECULAR BONE;

ANIMALS; ANIMALS, NEWBORN; CARTILAGE; CERVICAL VERTEBRAE; DISEASE PROGRESSION; DOGS; MUCOPOLYSACCHARIDOSIS I; ODONTOID PROCESS; SPINAL DISEASES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84877026416     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.03.014     Document Type: Article

References (37)

1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The metabolic and molecular bases of inherited disease 2001, 3421-3452. McGraw-Hill, New York. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Scott H.S., Bunge S., Gal A., Clarke L.A., Morris C.P., Hopwood J.J. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat 1995, 6:288-302.
3. Tandon V., Williamson J.B., Cowie R.A., Wraith J.E. Spinal problems in mucopolysaccharidosis I (Hurler syndrome). J Bone Joint Surg Br 1996, 78:938-944.
4. Kachur E., Del Maestro R. Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation. Neurosurgery 2000, 47:223-228. discussion 228-9.
5. Weisstein J.S., Delgado E., Steinbach L.S., Hart K., Packman S. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop 2004, 24:97-101.
6. Belani K.G., Krivit W., Carpenter B.L., Braunlin E., Buckley J.J., Liao J.C., et al. Children with mucopolysaccharidosis: perioperative care, morbidity, mortality, and new findings. J Pediatr Surg 1993, 28:403-408. discussion 408-10.
7. Hite S.H., Peters C., Krivit W. Correction of odontoid dysplasia following bone-marrow transplantation and engraftment (in Hurler syndrome MPS 1H). Pediatr Radiol 2000, 30:464-470.
8. Miebach E., Church H., Cooper A., Mercer J., Tylee K., Wynn R.F., et al. The craniocervical junction following successful haematopoietic stem cell transplantation for mucopolysaccharidosis type I H (Hurler syndrome). J Inherit Metab Dis 2011, 34:755-761.
9. Thomas S.L., Childress M.H., Quinton B. Hypoplasia of the odontoid with atlanto-axial subluxation in Hurler's syndrome. Pediatr Radiol 1985, 15:353-354.
10. Arn P., Wraith J.E., Underhill L. Characterization of surgical procedures in patients with mucopolysaccharidosis type I: findings from the MPS I Registry. J Pediatr 2009, 154:859-864.
11. Kakkis E.D., McEntee M.F., Schmidtchen A., Neufeld E.F., Ward D.A., Gompf R.E., et al. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 1996, 58:156-167.
12. Sifuentes M., Doroshow R., Hoft R., Mason G., Walot I., Diament M., et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6years. Mol Genet Metab 2007, 90:171-180.
13. Thomas J.A., Jacobs S., Kierstein J., Van Hove J. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome. J Inherit Metab Dis 2006, 29:762.
14. Haskins M., Casal M., Ellinwood N.M., Melniczek J., Mazrier H., Giger U. Animal models for mucopolysaccharidoses and their clinical relevance. Acta Paediatr Suppl 2002, 91:88-97.
15. Menon K.P., Tieu P.T., Neufeld E.F. Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I. Genomics 1992, 14:763-768.
16. Herati R.S., Knox V.W., O'Donnell P., D'Angelo M., Haskins M.E., Ponder K.P. Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy. Mol Genet Metab 2008, 95:142-151.
17. Dickson P.I., Hanson S., McEntee M.F., Vite C.H., Vogler C.A., Mlikotic A., et al. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I. Mol Genet Metab 2010, 101:115-122.
18. Smith L.J., Martin J.T., Szczesny S.E., Ponder K.P., Haskins M.E., Elliott D.M. Altered lumbar spine structure, biochemistry, and biomechanical properties in a canine model of mucopolysaccharidosis type VII. J Orthop Res 2010, 28:616-622.
19. Muenzer J., Wraith J.E., Clarke L.A. I ICPoMaToM. mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 2009, 123:19-29.
20. Rowan D.J., Tomatsu S., Grubb J.H., Montano A.M., Sly W.S. Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII. J Inherit Metab Dis 2012.
21. Shull R.M., Walker M.A. Radiographic findings in a canine model of mucopolysaccharidosis I. Changes associated with bone marrow transplantation. Invest Radiol 1988, 23:124-130.
22. Smith L.J., Baldo G., Wu S., Liu Y., Whyte M.P., Giugliani R., et al. Pathogenesis of lumbar spine disease in mucopolysaccharidosis VII. Mol Genet Metab 2012.
23. Smith L.J., Martin J.T., O'Donnell P., Wang P., Elliott D.M., Haskins M.E., et al. Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogs. Mol Genet Metab 2012.
24. Wilson S., Hashamiyan S., Clarke L., Saftig P., Mort J., Dejica V.M., et al. Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities. Am J Pathol 2009, 175:2053-2062.
25. Li Z., Yasuda Y., Li W., Bogyo M., Katz N., Gordon R.E., et al. Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J Biol Chem 2004, 279:5470-5479.
26. Simonaro C.M., D'Angelo M., He X., Eliyahu E., Shtraizent N., Haskins M.E., et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 2008, 172:112-122.
27. Simonaro C.M., Ge Y., Eliyahu E., He X., Jepsen K.J., Schuchman E.H. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci USA 2010, 107:222-227.
28. Clarke L.A. Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: glycosaminoglycan storage is merely the instigator. Rheumatology 2011, 50(Suppl. 5):v13-v18.
29. Lefebvre V., Smits P. Transcriptional control of chondrocyte fate and differentiation. Birth Defects Res C Embryo Today 2005, 75:200-212.
30. Koyama E., Golden E.B., Kirsch T., Adams S.L., Chandraratna R.A., Michaille J.J., et al. Retinoid signaling is required for chondrocyte maturation and endochondral bone formation during limb skeletogenesis. Dev Biol 1999, 208:375-391.
31. Minina E., Kreschel C., Naski M.C., Ornitz D.M., Vortkamp A. Interaction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Dev Cell 2002, 3:439-449.
32. Tamamura Y., Otani T., Kanatani N., Koyama E., Kitagaki J., Komori T., et al. Developmental regulation of Wnt/beta-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification. J Biol Chem 2005, 280:19185-19195.
33. Kronenberg H.M. Developmental regulation of the growth plate. Nature 2003, 423:332-336.
34. Lin X. Functions of heparan sulfate proteoglycans in cell signaling during development. Development 2004, 131:6009-6021.
35. Oussoren E., Brands M.M.M.G., Ruijter G.J.G., der Ploeg ATv, Reuser A.J.J. Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options. Biochim Biophys Acta 2011, 1812:1542-1556.
36. Simsa-Maziel S., Monsonego-Ornan E. Interleukin-1beta promotes proliferation and inhibits differentiation of chondrocytes through a mechanism involving down-regulation of FGFR-3 and p21. Endocrinology 2012, 153:2296-2310.
37. MacRae V.E., Farquharson C., Ahmed S.F. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J Endocrinol 2006, 189:319-328.